Back to Search
Start Over
Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
- Source :
- BMC Cancer; 1/14/2021, Vol. 21 Issue 1, p1-10, 10p
- Publication Year :
- 2021
-
Abstract
- <bold>Background: </bold>Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF V600-mutated mCRC.<bold>Methods: </bold>This real-world, multicenter, retrospective, observational study included patients with BRAF V600-mutated mCRC treated in eight hospitals in Spain. The primary endpoints were overall survival (OS) and progression-free survival (PFS); overall response rate (ORR) and disease control rate (DCR) were also assessed. The effect of first- and second-line treatment type on OS, PFS, ORR, and DCR were evaluated, plus the impact of systemic inflammatory markers on these outcomes. A systemic inflammation score (SIS) of 1-3 was assigned based on one point each for platelet-lymphocyte ratio (PLR) ≥200, neutrophil-lymphocyte ratio (NLR) ≥3, and serum albumin < 3.6 g/dL.<bold>Results: </bold>Of 72 patients, data from 64 were analyzed. After a median of 69.1 months, median OS was 11.9 months and median first-line PFS was 4.4 months. First-line treatment was triplet chemotherapy-antiangiogenic (12.5%), doublet chemotherapy-antiangiogenic (47.2%), doublet chemotherapy-anti-EGFR (11.1%), or doublet chemotherapy (18.1%). Although first-line treatment showed no significant effect on OS, antiangiogenic-based regimens were associated with prolonged median PFS versus non-antiangiogenic regimens. Negative predictors of survival with antiangiogenic-based treatment were NLR, serum albumin, and SIS 1-3, but not PLR. Patients with SIS 1-3 showed significantly prolonged PFS with antiangiogenic-based treatment versus non-antiangiogenic-based treatment, while those with SIS=0 showed no PFS benefit.<bold>Conclusions: </bold>Antiangiogenic-based regimens, SIS, NLR, and albumin were predictors of survival in patients with mCRC, while SIS, NLR and serum albumin may predict response to antiangiogenic-based chemotherapy.<bold>Trial Registration: </bold>GIT-BRAF-2017-01. [ABSTRACT FROM AUTHOR]
- Subjects :
- COLORECTAL cancer
METASTASIS
TREATMENT effectiveness
LYMPHOCYTES
SERUM albumin
SURVIVAL
RESEARCH
NEOVASCULARIZATION inhibitors
GENETIC mutation
INFLAMMATION
BLOOD platelets
RESEARCH methodology
RETROSPECTIVE studies
PROGNOSIS
EVALUATION research
NEUTROPHILS
COMPARATIVE studies
TRANSFERASES
RESEARCH funding
LONGITUDINAL method
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Volume :
- 21
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- BMC Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 148112633
- Full Text :
- https://doi.org/10.1186/s12885-020-07758-5